Clinical Trial Search

Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -17.1; -13.5 units on a scale — p=0.005

Primary: Pediatric Anxiety Rating Scale (Measures the Severity of Anxiety Symptoms) — 16.33; 17.62; 11.58; 16.05 units on a scale

Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies. — 213; 217; 213; 217 Participants

Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale

Primary: IVH at 5 Postnatal Days — 25; 40 IVH

Primary: Participant Satisfaction on Day 84 for 2 Different Delivery Mechanisms for Etanercept, Modified Intent-to-treat Population — 8.3; 7.2 units on a scale — p=<0.001

Primary: Incidence Rate of Treatment Success — 126; 94 participants

Primary: Clinical Global Impressions-Bipolar Mania Improvement — 2.49; 2.73; 1.70 units on a scale

Primary: Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) — -0.96; -1.15; -1.71; -1.56 percentage of glycosylated hemoglobin — p=<0.001

Primary: Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks — -0.27; -0.84 Percentage — p=< 0.0001

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — 0.15; -0.52; -0.56; -0.65 percentage glycosylated hemoglobin — p=<0.001

Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0-4 Hours (AUC0-4h) Response — 0.87; 2.51 Percent of predicted — p=0.092

Primary: Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event — 22; 41 Percentage of participants — p=0.038

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.42; -0.99; -0.22; -0.91 percentage glycosylated hemoglobin — p=<0.001

Primary: Geometric Mean Titer — 3.36; 2.61; 2.46; 2.41 GMT fold increase from baseline